Justin Balko Archive — Page 2 of 3
-
May 26, 2016
Precision medicine already changing cancer treatment strategies
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. -
April 21, 2016
Study explores how some breast cancers resist treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. -
March 3, 2016
Melanoma response to immune therapy
Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy. -
December 10, 2015
VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’
Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support. -
November 20, 2014
Gene mutation linked to breast cancer therapy resistance
A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy. -
October 23, 2014
VICC investigators earn breast cancer grants
The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies. -
July 31, 2014
VICC investigators land Komen breast cancer research grants
Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.